Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $80.00 target price on the biotechnology company's stock. HC Wainwright's target price suggests a potential upside of 408.26% from the stock's current price.

Several other research analysts have also commented on ARWR. Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com upgraded Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, May 14th. Citigroup lowered their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Finally, B. Riley reissued a "buy" rating and set a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $42.13.

Arrowhead Pharmaceuticals Trading Up 0.2%

NASDAQ ARWR opened at $15.74 on Tuesday. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $30.41. The company has a 50 day moving average price of $13.30 and a 200 day moving average price of $17.76. The firm has a market cap of $2.17 billion, a PE ratio of -3.04 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same quarter in the previous year, the company earned ($1.02) earnings per share. As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the sale, the chief executive officer now owns 3,921,255 shares of the company's stock, valued at $45,055,219.95. The trade was a 1.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 275,880 shares of company stock valued at $4,034,037. Corporate insiders own 4.30% of the company's stock.

Institutional Trading of Arrowhead Pharmaceuticals

Large investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after purchasing an additional 2,774,933 shares in the last quarter. Empowered Funds LLC lifted its position in Arrowhead Pharmaceuticals by 6.9% in the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock worth $194,000 after purchasing an additional 979 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock valued at $22,189,000 after purchasing an additional 447,456 shares during the period. Dynamic Technology Lab Private Ltd raised its stake in shares of Arrowhead Pharmaceuticals by 40.9% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 26,969 shares of the biotechnology company's stock worth $343,000 after buying an additional 7,827 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in Arrowhead Pharmaceuticals during the first quarter valued at about $514,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.